KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.

Xavier Sáez-Llorens, Shibadas Biswal, Charissa Borja-Tabora, LakKumar Fernando, Mengya Liu, Derek Wallace, Nicolas Folschweiller, Humberto Reynales, Inge LeFevre, TIDES Study Group

Am J Trop Med Hyg 108(4) 722-726

PMID36878213
PMCIDPMC10077010
DOI10.4269/ajtmh.22-0673
发表日期2023-03-06
摘要

摘要

In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57 months later (patients received the second dose 3 months after the first dose). Two of these participants experienced repeat infection with the same serotype (i.e., homotypic reinfection). In comparison with placebo, the relative risk of a subsequent episode of symptomatic dengue was 0.19 (95% CI, 0.07-0.54) in TAK-003 recipients. Based on the small number of subsequent episodes, these data suggest a potential incremental effect of TAK-003 beyond prevention of the first episode of symptomatic dengue after vaccination.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。